Scientists have demonstrated that the APOE4 gene variant, which increases risk for Alzheimer’s but decreases risk of glaucoma in humans, blocks a disease cascade that leads to the destruction of retinal ganglion cells in glaucoma. Additionally, they showed in mouse models that the death of retinal ganglion cells – the cause of vision loss in glaucoma – can be prevented by using medications to inhibit a molecule called Galectin-3, which is regulated by the APOE gene. These findings taken together emphasize the critical role of APOE in glaucoma and suggest that Galectin-3 inhibitors hold promise as a glaucoma treatment, according to the authors.
Tag: Apoe 4
WVU researcher says gene discovery may lead to new tests, treatments for Alzheimer’s in women
Women make up two-thirds of Americans who have Alzheimer’s disease, yet scientists have yet to determine what makes them so susceptible to the condition. Bernard Schreurs, a researcher with the West Virginia University School of Medicine and Rockefeller Neuroscience Institute, directs the West Virginia Alzheimer’s…